- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02350153
Cushing´s Disease Epidemiology in Sweden
National Swedish Study in Cushing´s Disease Incidence and Outcomes
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This study is a retrospective nationwide study of all patients in Sweden with diagnosis CD between 1987 and 2013 were baseline data at diagnosis, information about the different treatments and follow-up data is going to be obtained by reviewing patients' medical journals. This information as well as the exact diagnose criteria for each patient are going to be extracted by Endocrinologists in all University Hospitals in Sweden. An expert group at the Sahlgrenska University Hospital in Gothenburg will put together the data.By the use of the Swedish Personal Number, the investigators are going to obtain information about both patients' and background population co-morbidities which have been collected in the different Swedish Registers.
Primary aim:
To study mortality of CD in Sweden.
Secondary aims:
- To study the influence of CD on myocardial infarction
- To study the influence of CD on stroke
- To study the influence of CD on cancer
- To study the influence of CD on hip fracture risk
- To study incidence and prevalence of CD in Sweden.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Vastra Gotaland Region
-
Gothenburg, Vastra Gotaland Region, Sverige, 413 45
- Sahlgrenska University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- All patients registered with Cushing's Disease in Sweden since 1987 in the statistical database for in- and out-patients, at the Swedish National Board of Health and Welfare will be included in the study.
Exclusion Criteria:
- No
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Patients with verified Cushing's Disease
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mortality
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years.
|
If event (death) has been occured during the observation period.
Data obtained by the Swedish Cause Of Death Register (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
influence of Cushing's Disease on myocardial infarction
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (myocardial infarction) has been occured during the observation period.Data obtained by the Swedish Register of In- and Out-patient Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on stroke
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (stroke) has been occured during the observation period.Data obtained by the Swedish Register of In- and Out-patient Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on cancer
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (cancer) has been occured during the observation period.Data obtained by the Swedish Register of Cancer Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on hip fracture risk
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (hip fracture) has been occured during the observation period.Data obtained by the Swedish Register of Hip Fractures (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
incidence of Cushing's Disease in Sweden
Tidsramme: Assessed up to 20 years.
|
Validation of Data obtained by The Swedish Board of Health and Welfare by reviewing all patients' journals
|
Assessed up to 20 years.
|
|
prevalence of Cushing's Disease in Sweden
Tidsramme: Assessed up to 20 years.
|
Validation of Data obtained by The Swedish Board of Health and Welfare by reviewing all patients' journals
|
Assessed up to 20 years.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Gudmundur Johannsson, Professor, Vastra Gotaland Region, Sahlgrenska University Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Neoplasmer, kirtel og epitel
- Sygdomme i det endokrine system
- Neoplasmer i endokrine kirtler
- Hypothalamus sygdomme
- Hyperpituitarisme
- Hypofysesygdomme
- Adenom
- Hypofyse neoplasmer
- ACTH-udskillende hypofyseadenom
- Hypofyse ACTH Hypersekretion
Andre undersøgelses-id-numre
- NSSCDIO
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .